← Back to Clinical Trials
Recruiting NCT06553469

NCT06553469 Efficacy of Sacral Nerve Modulation on Urinary and Defecation Dysfunction After Spinal Cord Injury:A Prospective, Single-arm Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06553469
Status Recruiting
Phase
Sponsor Qilu Hospital of Shandong University
Condition Cystometry
Study Type OBSERVATIONAL
Enrollment 41 participants
Start Date 2023-12-01
Primary Completion 2025-12-01

Trial Parameters

Condition Cystometry
Sponsor Qilu Hospital of Shandong University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 41
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-01
Completion 2025-12-01
Interventions
sacral neuromodulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to investigate the long-term efficacy of sacral nerve modulation surgery in the treatment of neurogenic lower urinary tract dysfunction caused by incomplete spinal cord injury, as well as its preventive effect on complications of neurogenic lower urinary tract dysfunction. We will use urodynamic examination results such as maximum bladder capacity and detrusor leak point pressure, combined with renal function and urinary ultrasound results, as our evaluation indicators. Follow up evaluations will be conducted at 6 and 12 months after permanent implantation, and periodic comparisons will be made with baseline data to gain a more comprehensive understanding of the effectiveness and safety of sacral nerve regulation surgery.

Eligibility Criteria

Inclusion Criteria: * Age over 18 years old, gender not limited * Diagnosed with urinary and defecation dysfunction caused by spinal cord injury * Urodynamic examination suggests bladder dysfunction * ASIA spinal cord injury classification: B, C, or D * Safe bladder capacity\>100ml * Patients who can undergo sacral nerve regulation surgery after evaluation * If you plan not to combine medication during the study period, you need to stop taking the medication for at least 7 days before the screening period. If you plan to continue drug treatment during the study period, you need to maintain the same dosage or stop taking the medication after evaluation by a doctor. * Voluntarily participate in this clinical study, and the subjects sign a written informed consent form before the start of the study. * After testing treatment, if any of the following conditions are met, permanent implantation of a sacral nerve stimulator is feasible① The average daily frequency of urination during the last

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology